Trevi Therapeutics (TRVI) Now Covered by BMO Capital Markets
Analysts at BMO Capital Markets initiated coverage on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $15.00 price target on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 50.91% from the company’s previous close.
TRVI has been the topic of several other reports. Stifel Nicolaus began coverage on Trevi Therapeutics in a research note on Monday. They set a “buy” rating and a $20.00 price objective on the stock. Leerink Swann began coverage on Trevi Therapeutics in a research note on Monday. They set an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, Trevi Therapeutics currently has an average rating of “Buy” and a consensus price target of $16.75.
Shares of NASDAQ:TRVI opened at $9.94 on Monday. Trevi Therapeutics has a 1-year low of $7.18 and a 1-year high of $10.62.
About Trevi Therapeutics
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Further Reading: What is a Fibonacci Channel?
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.